4.380USD-3.31%Mkt Cap: 282.54M USDP/E: —Last update: 2026-05-26
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pip…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap282.54M USD
Enterprise Value151.79M USD
Revenue (TTM)157.08M USD
Gross Profit113.49M USD
Net Income (TTM)-74.62M USD
Revenue/Share2.482 USD
Last Price4.380 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees293
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS5560991094
Valuation
P/E (Trailing)—
P/E (Forward)-3.00
PEG—
EV/EBITDA-2.68
EV/Revenue0.97
P/S1.72
P/B4.83
EPS (TTM)-1.11
EPS (Forward)-1.41
52W Range
1.18592% of range4.640
52W High4.640 USD
52W Low1.185 USD
Profitability
Gross Margin75.91%
Oper. Margin-160.96%
EBITDA Margin-36.01%
Profit Margin-49.91%
ROE-134.23%
ROA-29.05%
Growth
Revenue Growth57.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-81.04M USD
CapEx (TTM)1.91M USD
FCF Margin7.54%
FCF Yield4.19%
Net Debt-117.72M USD
Net Debt/EBITDA2.08
Balance Sheet
Debt/Equity0.66
Current Ratio1.90
Quick Ratio1.72
Book Value/Sh0.8780 USD
Cash/Share2.426 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.3 (Buy)
Target (Mean)6.750 USD
Target Range4.000 USD – 9.000 USD
# Analysts4
Ownership
Shares Out.63.56M
Float55.60M
Insiders3.43%
Institutions70.16%
Short Interest
Short Ratio4.0d
Short % Float4.78%
Short % Out.4.61%
Shares Short2.93M
Short (prev mo.)3.78M
Technical
SMA 503.302 (+32.6%)
SMA 2002.095 (+109.1%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)1.20M
Avg Vol (10d)2.34M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—